Wells Fargo analyst Eva Fortea Verdejo upgraded Bicara Therapeutics (BCAX) to Equal Weight from Underweight with an unchanged price target of $8.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
- Why Is Bicara Therapeutics Stock (BCAX) Down 30% Today?
- Promising Efficacy and Survival Data Drive Buy Rating for Bicara Therapeutics
- Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa in HPV-Negative HNSCC Drives Buy Rating
- Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally